Single-center Investigator Initiated Pilot Study Investigating the Tumor Response of Squamous Cell Carcinoma Lesions in Patients Under Lapatinib Treatment

Inclusion criteria: * Age ≥ 18 years * Diagnosis of histologically confirmed cutaneous SCC stage Tis-T2N0 for which surgical treatment is considered suitable. * In case of SCC, patients must present with a minimum of two co-existing AK lesions. In case of Keratoacanthoma, one lesion of sufficient size (=1cm) is acceptable. * All included patients must have both FFPE and frozen material available. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate organ system function Exclusion criteria: * Subjects who have current active hepatic or biliary disease * Other non-controlled malignancy * Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding. * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of study treatment. * Presence of uncontrolled infection * History of any one or more of the following cardiovascular conditions within the past 6 months:Cardiac angioplasty or stenting;Myocardial infarction;Unstable angina;Coronary artery bypass graft surgery;Symptomatic peripheral vascular disease; Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA) * Poorly controlled hypertension * History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. * Prior exposure to the study drug lapatinib * Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer